登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002737 证券简称：葵花药业 公告编号：2025-057 葵花药业集团股份有限公司关于盐酸非索非那定口服混悬液获得药品注册证书的公告 一、 药物的基本情况 季节性过敏性鼻炎: 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）子公司于近日收到国家药品监督管理局下发 的关于盐酸非索非那定口服混悬液获批注册的药品注册证书，现将有关情况公告如下： 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。药品生产企业应 当符合药品生产质量管理规范要求方可生产销售。 9、适应症： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 1、药品通用名称：盐酸非索非那定口服混悬液 适用于缓解2岁及以上儿童和成人的季节性过敏性鼻炎的相关症状。如打喷，流鼻涕，鼻、上腭、喉咙 发痒，眼睛发痒、潮湿、发红。 公司将重点强化产品研发、成果转化、量产上市过程中的质量与工艺管控，鉴于医药行业产品与业务受 行业政策、 ...

证券日报网讯 9月1日晚间，葵花药业发布公告称，子公司于近日收到国家药品监督管理局下发的关于 盐酸非索非那定口服混悬液获批注册的药品注册证书。 （文章来源：证券日报） ...

格隆汇9月1日丨葵花药业(002737.SZ)公布，公司子公司于近日收到国家药品监督管理局下发的关于盐 酸非索非那定口服混悬液获批注册的药品注册证书。盐酸非索非那定口服混悬液应用于抗过敏领域，该 产品的获批将有助于公司拓展产品管线、完善品类布局、提升治疗领域覆盖，公司将加速推进产品的后 续量产上市，实现研发成果快速转化。责任编辑：钟离 ...

格隆汇9月1日丨葵花药业(002737.SZ)公布，公司子公司于近日收到国家药品监督管理局下发的关于盐 酸非索非那定口服混悬液获批注册的药品注册证书。盐酸非索非那定口服混悬液应用于抗过敏领域，该 产品的获批将有助于公司拓展产品管线、完善品类布局、提升治疗领域覆盖，公司将加速推进产品的后 续量产上市，实现研发成果快速转化。 ...

葵花药业公告，子公司于近日收到国家药品监督管理局下发的关于盐酸非索非那定口服混悬液获批注册 的药品注册证书。药品规格为120ml:0.72g，注册分类为化学药品3类，为处方药。该药品适用于缓解2 岁及以上儿童和成人的季节性过敏性鼻炎相关症状，以及6个月及以上儿童和成人的慢性特发性荨麻疹 皮肤症状。 ...

葵花药业9月1日公告，子公司于近日收到国家药品监督管理局下发的关于盐酸非索非那定口服混悬液获 批注册的药品注册证书。药品规格为120ml:0.72g，注册分类为化学药品3类，为处方药。该药品适用于 缓解2岁及以上儿童和成人的季节性过敏性鼻炎相关症状，以及6个月及以上儿童和成人的慢性特发性荨 麻疹皮肤症状。 ...

Financial Performance - In 2024, the company reported a revenue of 3.377 billion yuan, a year-on-year decrease of 40.76% [2] - The net profit attributable to shareholders was 492 million yuan, down 56.03% year-on-year [2] - The net profit after deducting non-recurring items was 345 million yuan, a decline of 65.65% year-on-year [2] - Basic earnings per share were 0.84 yuan, with a weighted average return on equity of 10.76% [2] Expense Structure - Total operating expenses for 2024 amounted to 955 million yuan, a reduction of 981 million yuan year-on-year, resulting in an expense ratio of 28.28% [5] - Sales expenses significantly decreased by 68.46% due to channel adjustments, while R&D expenses slightly decreased by 3.51% [5] - Financial expenses increased by 27.73% year-on-year [5] Business Segmentation - Revenue from traditional Chinese medicine was 2.463 billion yuan, down 40.55%, accounting for 72.96% of total revenue [5] - The core product, liver-protecting tablets, achieved sales exceeding 1 billion yuan, but respiratory products saw a significant decline in sales due to high base effects and reduced demand [5] - Revenue from chemical drugs was 712 million yuan, a decrease of 47%, representing 21% of total revenue [5] Product Development - The company has over 60 children's products covering cold, digestive, and respiratory fields, with nearly 30 products achieving sales over 10 million yuan [5] - Adult medications focus on cardiovascular and rheumatic diseases, maintaining a leading market share for liver-protecting tablets [5] - Ten chemical drugs and three traditional Chinese medicine products are in the pilot testing stage, with some products already accepted for review [5] R&D Investment - R&D investment for 2024 was 124 million yuan, accounting for 3.68% of revenue, with a continued focus on the "buy, modify, connect, research, and substitute" strategy, particularly in children's and chronic disease medications [5] Dividend Distribution - The company plans to distribute a cash dividend of 5 yuan per 10 shares (including tax) for 2024 [6]